Supplemental Table 1 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
Key Points
Key points are not available for this paper at this time.
Abstract
Supplemental Table 1: Dose limiting toxicities for run-in phase of ANA10.
Supplemental Table 1 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial | Synapse